Innovative Therapy Improves Lives of People With Neuroendocrine Tumors
When Jay Elsten’s neuroendocrine tumors no longer were responding to traditional treatment, Mayo Clinic offered him a recently approved nuclear medicine therapy. And it worked. Within a week, Jay’s symptoms were gone.
Jay
Elsten’s medical concerns started subtly with just some itching and rashes on
his legs. A visit to his primary care physician in 2012 led to a diagnosis of
hepatitis, a prescription for antibiotics and a recommendation to call again if
Jay didn’t feel better in a few days.
“In
three days, I couldn’t keep anything down,” Jay says. “I’d lost 40
pounds in a week, and (my doctor) said to go to the ER.”
That hospital visit led to more tests, including a CT scan. Results showed a tumor on Jay’s pancreas. At that point, Jay, who lives in Missouri, had to decide where to go next.
“It was too rare, what I had. (My doctor) gave me three choices,” Jay says. “The business I was in before, I had dealings with people in Dodge Center, Minnesota, so I knew people up here. I thought, ‘I’ll go to Mayo because if I get in trouble, I know people up there that can help my wife.'”
An unusual diagnosis
When he arrived at Mayo Clinic in Rochester, a biopsy revealed that Jay had a neuroendocrine tumor on his pancreas. “Neuroendocrine tumors are really a collection of tumors that can arise anywhere in the body,” says Thorvardur Halfdanarson, M.D., a Mayo Clinic medical oncologist. “And not only can they arise anywhere in the body, but they behave very differently from one person to the next.”
For
example, some people experience diarrhea or pain as a result of these tumors,
while others have no symptoms, and the tumors are discovered only during an
imaging exam for something else. Neuroendocrine tumors can secrete hormones,
which often triggers symptoms. Some neuroendocrine tumors are slow-growing. Others
are aggressive.
“I was here to fight it from the beginning, and it’s what I intend on doing.”
Jay Elsten
“They
are still a big enigma, and for the most common ones — the small bowel
neuroendocrine tumors — we really don’t have a good understanding why people
get them,” Dr. Halfdanarson says.
Once
he learned his diagnosis, Jay knew what he needed to do. “I was here to
fight it from the beginning, and it’s what I intend on doing. I want to see my
kids graduate. I want to walk my daughter down the aisle. I intend on staying
around for a long time,” says Jay, who is married and has two children.
A tough battle
A Mayo Clinic care team that included specialists from Medical Oncology, Gastroenterology, Pulmonary Medicine, Surgery, Radiology, Nuclear Medicine and Pathology has supported Jay throughout his treatment.
“The
care plan never changes. Where other places, you get a new doctor, and they’ve
got a different idea,” Jay says. “They decided from the beginning
what they were going to do, and that’s the same plan that we’ve carried out
through the whole seven years.”
The plan started with chemotherapy. That shrank the cancer and gave Jay two years without any issues. But then the cancer spread to his liver. Chemotherapy did not effectively bring his neuroendocrine tumors in check at that point, and his team looked for other options.
In January 2018, the treatment Jay needed was approved by the Food and Drug Administration to treat the type of tumor he had: gastroenteropancreatic neuroendocrine tumors. That treatment is called lutetium Lu 177 dotatate, a peptide receptor radionuclide therapy, also referred to as PRRT.
“It’s
kind of a Trojan horse,” says Geoffrey
Johnson, M.D., Ph.D., chair of Mayo Clinic’s Division of
Nuclear Medicine, adding that the dotatate binds to receptors on the cancer
cells and the lutetium radiates the cells, killing them.
“PRRT
… is a therapy using a radioactive compound that sticks to the neuroendocrine
tumor cells. There are three components to it. There is what’s called a
somatostatin analog, which binds to the receptors of the tumor cells. And then
there is therapeutic radionuclide, or radioactive molecule, which is
therapeutic. And then there is almost like a glue that binds these things together,”
Dr. Halfdanarson says. “We inject this into a vein that circulates around
the body. It sticks to the tumor cells that express the somatostatin receptors.
Then this radiation molecule sits right on the tumor cell and kills the tumors
cells with radiation.”
Positron emission tomography imaging, with gallium Ga 68 dotatate, identified Jay as an ideal candidate for the new treatment. With this treatment, patients receive four doses, each eight weeks apart, with checkups about a month after each infusion. For most people, symptom improvement comes after the second dose.
A remarkable result
Jay
says that being able to take advantage of this kind of innovative therapy is
part of the advantage of the long-term care he’s received at Mayo Clinic. “The
longer I can push this disease off, things change,” he says.
“(Lutetium Lu 177 dotatate) is something that didn’t exist seven years ago
when I was first diagnosed.”
His
care team tried to set Jay’s expectations appropriately. “Dr. Halfdanarson
told me before I got the first treatment: ‘Don’t expect immediate results. It
usually takes two rounds before we see anything,'” Jay says.
“Within a week, I was back to normal. It was simply amazing.”
Jay Elsten
But
he was in for a surprise. “Within three or four days, the diarrhea
stopped,” Jay says. “It had shocked the tumor enough … it quit
producing that hormone. Within a week, I was back to normal. It was simply amazing.”
Rachel
Eiring, a medical oncology physician assistant, was part of Jay’s Mayo Clinic care
team during his lutetium Lu 177 dotatate treatments, and she was thrilled with
his results.
“I
think what’s absolutely remarkable about his story is the huge improvement in
his quality of life,” she says. “He went from … being in and out of
the hospital to being able to do the things that he wanted. That was exciting
to see somebody have such a big impact following just his first treatment.”
“It’s
been a great experience up here,” Jay says. “When I was in the
hospital in Joplin (Missouri) with all this, there was a patient in there, and
one of the nurses asked me if I would go talk to him about Mayo. I’m happy to
talk to anybody about Mayo. My family knows it. They probably get tired of
hearing about it. But it’s just an amazing place.”
Watch
this video to learn more about Jay’s story:
HELPFUL
LINKS
- Learn more about neuroendocrine tumors.
- Read about Nuclear Medicine at Mayo Clinic.
- Check out the departments of Radiology and Medical Oncology.
- Explore Mayo Clinic.
- Request an appointment.